Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
06/2000
06/15/2000WO2000034780A2 METHODS AND COMPOSITIONS USEFUL FOR TARGETING ACTIVATED VITRONECTIN RECEPTOR αvβ¿3?
06/15/2000WO2000034516A1 Detection of rantes gene promotor polymorphisms
06/15/2000WO2000034515A1 Use of factor x polymorphism in the diagnosis and treatment of factor x and/or factor xa mediated diseases
06/15/2000WO2000034511A2 Aβ-PEPTIDE SCREENING ASSAY
06/15/2000WO2000034483A2 Compounds and methods for treatment and diagnosis of chlamydial infection
06/15/2000WO2000034481A2 DRUG TARGETS IN $i(CANDIDA ALBICANS)
06/15/2000WO2000034477A2 Neuron-associated proteins
06/15/2000WO2000034474A2 Growth factor homolog zvegf3
06/15/2000WO2000034468A2 Muc-1 antagonists and methods of treating immune disorders
06/15/2000WO2000034467A1 Cancer cell vaccine
06/15/2000WO2000034334A1 DNA ENCODING A MAMMALIAN RECEPTOR (fb41a) AND USES THEREOF
06/15/2000WO2000034330A1 Cark protein and nucleic acid molecules and uses therefor
06/15/2000WO2000034303A1 METHODS OF MODULATING TUMOR NECROSIS FACTOR α-INDUCED EXPRESSION OF CELL ADHESION MOLECULES
06/15/2000WO2000034294A2 Tumor necrosis factor receptor homologue-1 ('trh1')
06/15/2000WO2000033917A1 Agents provided for treating tumors, based on liposomes, and containing tamoxifen
06/15/2000WO2000033885A1 Supramolecular complexes containing therapeutic agents
06/15/2000WO2000033876A1 Formulation with an improved therapeutic range, containing nucleotide synthesis inhibitors
06/15/2000WO2000033875A1 Chemotherapeutic composition and method
06/15/2000WO2000033864A1 Remedies for tactile failures
06/15/2000WO2000033862A1 Self-emulsifying compositions for drugs poorly soluble in water
06/15/2000WO2000033858A1 Cancer treatment composition and method using natural plant essential oils with signal transduction modulators
06/15/2000WO2000033857A1 Cancer treatment composition and method using natural plant essential oils
06/15/2000WO2000033856A1 Cancer treatment composition and method using signal transduction modulators and natural plant essential oils
06/15/2000WO2000033848A1 Methods and compositions for prevention and treatment of restenosis with non-steroidal anti-inflammatory drugs
06/15/2000WO2000033840A1 Use of acetylcholinesterase inhibitors on the modulation of the hypothalamic-pituitary-gonadal axis
06/15/2000WO2000033838A1 Vitronectin receptor antagonist
06/15/2000WO2000033825A2 Compositions and methods for amelioration of human female sexual dysfunction
06/15/2000WO2000033814A2 Method for administering agents to the central nervous system
06/15/2000WO2000033813A1 Administration of neurotrophic agents to the central nervous system
06/15/2000WO2000033810A1 Use of vitamin b12 in a nasal composition for delivering active agents to the central nervous system
06/15/2000WO2000033790A2 Methods and compositions for prevention and treatment of arterial lesions with non-steroidal anti-inflammatory drugs
06/15/2000WO2000023618A8 Polymorphism in a tgf-beta gene correlated to osteoporosis
06/15/2000WO2000011000A3 New compounds
06/15/2000WO2000010600A3 Activation and protection of t-cells (cd4+ and cd8+) using an h¿2? receptor agonist and other t-cell activating agents
06/15/2000WO2000010598A3 Recombinant botulinium toxin for the treatment of mucus hypersecretion
06/15/2000WO2000009107A3 Sulfonamides of n-containing heterocyclic thioesters for vision and memory disorders
06/15/2000WO2000005374A3 Molecules associated with cell proliferation
06/15/2000WO1999066951A3 Use of bi-specific antibodies for pre-targeting diagnosis and therapy
06/15/2000WO1999066051A3 Nek-related and bub1-related protein kinases
06/15/2000WO1999061452A3 acpS
06/15/2000WO1999014328A3 Secreted and transmembrane polypeptides and nucleic acids encoding the same
06/15/2000DE19857490A1 Cosmetic or dermatological skin-protective compositions, containing saturated and unsaturated phosphatidyl choline to give good barrier stabilizing and active agent penetrating effects
06/15/2000DE19857489A1 Cosmetic or dermatological skin-protective compositions, containing triglycerides and saturated and unsaturated phosphatidyl choline to give good barrier stabilizing effects
06/15/2000DE19857009A1 Zubereitung mit verbesserter therapeutischer Breite, enthaltend Nukleotidsyntheseinhibitoren Preparation with improved therapeutic index containing nucleotide synthesis
06/15/2000CA2746535A1 Compounds and methods for treatment and diagnosis of chlamydial infection
06/15/2000CA2354644A1 Muc-1 antagonists and methods of treating immune disorders
06/15/2000CA2354612A1 Tumor necrosis factor receptor homologue-1 ("trh1")
06/15/2000CA2354266A1 Formulation with an improved therapeutic range, containing nucleotide synthesis inhibitors
06/15/2000CA2354233A1 Self-emulsifying compositions for drugs poorly soluble in water
06/15/2000CA2354232A1 Compounds and methods for treatment and diagnosis of chlamydial infection
06/15/2000CA2354188A1 Cancer cell vaccine
06/15/2000CA2354150A1 Detection of rantes gene promotor polymorphisms
06/15/2000CA2354035A1 Use of acetylcholinesterase inhibitors on the modulation of the hypothalamic-pituitary-gonadal axis
06/15/2000CA2353797A1 Neuron-associated proteins
06/15/2000CA2353773A1 Cark protein and nucleic acid molecules and uses therefor
06/15/2000CA2353616A1 Assays for compounds which increase phospholipase a2 activity
06/15/2000CA2353552A1 Supramolecular complexes containing therapeutic agents
06/15/2000CA2353525A1 Drug targets in candida albicans
06/15/2000CA2353516A1 Cancer treatment composition and method using natural plant essential oils
06/15/2000CA2353476A1 Cancer treatment composition and method using signal transduction modulators and natural plant essential oils
06/15/2000CA2353475A1 Cancer treatment composition and method using natural plant essential oils with signal transduction modulators
06/15/2000CA2353415A1 Vitronectin receptor antagonist
06/15/2000CA2351452A1 Methods and compositions useful for targeting activated vitronectin receptor .alpha.v.beta.3
06/14/2000EP1008349A1 Neovascularization promoters
06/14/2000EP1008341A1 Glucose-containing preparation
06/14/2000EP1007738A1 Methods for analyzing ltc4 synthase polymorphisms and diagnostic use
06/14/2000EP1007714A1 Regulatory sequences capable of conferring expression of a heterologous dna sequence in endothelial cells in vivo and uses thereof
06/14/2000EP1007696A1 Il-13 receptor specific chimeric proteins and uses thereof
06/14/2000EP1007695A2 Rab proteins
06/14/2000EP1007668A1 Human pancreatitis-associated protein, pap-2
06/14/2000EP1007665A1 Two human homologues of galectin-5
06/14/2000EP1007663A2 Human proteins
06/14/2000EP1007652A1 Transgenic animals with knocked-in vec receptor genes and uses thereof
06/14/2000EP1007565A2 Transgenic animals with disrupted npy y1 receptor genes
06/14/2000EP1007563A1 Hm74a receptor
06/14/2000EP1007562A1 TUMOR NECROSIS FACTOR RECEPTOR RELATED PROTEINS TANGO-63d AND TANGO-63e
06/14/2000EP1007537A1 Receptor protein designated 2f1
06/14/2000EP1007535A1 Methods and compositions for diagnosis and treatment of breast cancer
06/14/2000EP1007101A2 Improvements in or relating to diagnostic/therapeutic agents
06/14/2000EP1007093A1 Methods for treating disorders by using interleukin-9 and its antagonists
06/14/2000EP1007092A1 A process for inhibiting complement activation via the alternative pathway
06/14/2000EP1007076A1 Method of antagonizing the human src sh2 domain
06/14/2000EP1007071A1 Methods of treating renal disease with a gastrin releasing peptide receptor antagonist
06/14/2000EP1007069A1 Novel coding sequences
06/14/2000EP1007059A1 Methods of and compositions for potentiating the action of agents active on cell wall sites of the susceptible bacteria
06/14/2000EP1007058A1 USE OF $i(N)-SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL COMPOUNDS IN COMBINATION THERAPY FOR TREATING HEPATITIS VIRUS INFECTIONS
06/14/2000EP1007055A1 Methods for the administration of amifostine
06/14/2000EP1007048A1 Identification of agents for use in the treatment of alzheimer's disease
06/14/2000EP1007034A1 Compositions containing bergamottin for increasing the oral bioavailability of pharmaceutical agents
06/14/2000EP1007033A1 Lymphocyte function antigen-1 antagonists
06/14/2000EP1007026A1 Integrin antagonists
06/14/2000EP1007019A2 Cholesterol-lowering therapy
06/14/2000EP1007017A1 New formulation for inhalation having a poured bulk density of 0.28 to 0.38 g/ml, a process for preparing the formulation and the use thereof
06/14/2000EP1007012A1 Taste-masked microcapsule compositions and methods of manufacture
06/14/2000EP1007003A1 Cationic amphiphile compositions for intracellular delivery of therapeutic molecules
06/14/2000EP1006794A1 A method for treating or preventing alzheimer's disease
06/14/2000EP0830145B1 Formulations comprising leflunomide
06/14/2000EP0822812A4 Topical treatment and/or prevention of sagging subcutaneous muscle and overlying cutaneous tissue using acetylcholine precursors and catecholamines
06/14/2000CN1256700A Biodegradable terephthalate polyester-poly(phosphate) polymers, compositions, articles,and method for making and using the same
06/14/2000CN1256631A Methods and composition for treating fungal infections in mannals
1 ... 971 972 973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 ... 1151